迈瑞医疗：血球产品作为核心，在捷克市占率已达25%

Core Viewpoint - The company, Mindray Medical (300760.SZ), is experiencing significant growth in its in-vitro diagnostic (IVD) business in the Czech Republic, with increasing sales and market share across various product lines [1] Group 1: Business Progress in Czech Republic - The sales revenue and market share of Mindray's IVD business in the Czech Republic are increasing year by year [1] - The company has achieved a 25% market share in hematology products, which are considered core products [1] - Mindray's products have been installed in private chain groups such as AKESO, IFCOR, and Kli**cka Biochemia, indicating strong market penetration [1] Group 2: Product Line Expansion - Mindray has made breakthroughs in various product lines including hematology, biochemistry, immunology, urinalysis, and flow cytometry [1] - The M980 chemical immunoassay cascade line has been installed at **BH Olomouc Hospital, showcasing the company's technological advancements [1] - Other diagnostic products have been installed in teaching hospitals such as Nemocnice Na Homolce and Fakultní nemocnice Brno, reflecting a comprehensive expansion of the IVD product lines [1]